Citadel Advisors’s Phaxiam Therapeutics PHXM Stock Holding History
Bought
Maintained
Sold
Other funds holding PHXM
Citadel Advisors's PHXM Position: Q3 2023 in Review
Citadel Advisors sold out of Phaxiam Therapeutics (PHXM) in Q3 2023, closing a stake of 1,661 shares — an estimated $12.1K sold.
Citadel Advisors first reported a position in PHXM in Q1 2021 and held it in 9 quarters. The position peaked at $173K in Q4 2021. 3 funds tracked by Wall St. Rank hold PHXM as of Q3 2023.
- Citadel Advisors reported no remaining Phaxiam Therapeutics position as of Q3 2023 after selling out during the quarter.
- Citadel Advisors sold 1,661 Phaxiam Therapeutics shares in Q3 2023, an estimated $12.1K.
- Citadel Advisors first reported a position in Phaxiam Therapeutics in Q1 2021 and held it in 9 quarters.
- Citadel Advisors's Phaxiam Therapeutics position peaked at $173K in Q4 2021.
- 3 funds tracked by Wall St. Rank held Phaxiam Therapeutics as of Q3 2023.
Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.